Search results
Showing 466 to 478 of 478 results for cost benefit of cancer drugs
The Marmot Review summarised the importance the impact of addressing inequalities in health in later life and investing in the early years to preventing ill health later in life.
Technology appraisal data: appraisal recommendations Technology appraisal data: cancer appraisal recommendations Compliance with...
Thousands of people a year could benefit from new twice-a-day tablet for advanced breast cancer
We've published final draft guidance recommending capivasertib with fulvestrant, which means the treatment will be funded immediately through the Cancer Drugs Fund.
Record number of positive recommendations for blood cancer treatments
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
Additional evidence needed to assess histology-independent cancer drugs
A paper published and co-authored by NICE staff looks at how histology-independent cancer drugs might be appraised.
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
NICE has recommended a new option for people with difficult-to-treat multiple myeloma
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
Ovarian cancer patients to have NICE-approved drug combination option on Cancer Drugs Fund
A potentially life-extending drug combination for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer will now be available on the Cancer Drugs Fund (CDF), following its approval by NICE in draft guidance published today.
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
More than 1,000 people each year will benefit from NICE's recommendation.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).